Role of AMP-activated protein kinase in mechanism of metformin action.

G. Zhou; R. Myers; Y. Li; Y. Chen; X. Shen; J. Fenyk-Melody; M. Wu; J. Ventre; T. Doebber; N. Fujii; N. Musi; M. Hirshman; L. Goodyear; D. Moller

DOI:10.1172/JCI13505

Corpus ID: 9899292

Role of AMP-activated protein kinase in mechanism of metformin action.

@article{Zhou2001RoleOA,
  title={Role of AMP-activated protein kinase in mechanism of metformin action.},
  author={G. Zhou and R. Myers and Y. Li and Y. Chen and X. Shen and J. Fenyk-Melody and M. Wu and J. Ventre and T. Doebber and N. Fujii and N. Musi and M. Hirshman and L. Goodyear and D. Moller},
  journal={The Journal of clinical investigation},
  year={2001},
  volume={108 8},
  pages={
          1167-74
        }
}

G. Zhou, R. Myers, +11 authors D. Moller
Published 2001
Chemistry, Medicine
The Journal of clinical investigation

Metformin is a widely used drug for treatment of type 2 diabetes with no defined cellular mechanism of action. Its glucose-lowering effect results from decreased hepatic glucose production and increased glucose utilization. Metformin's beneficial effects on circulating lipids have been linked to reduced fatty liver. AMP-activated protein kinase (AMPK) is a major cellular regulator of lipid and glucose metabolism. Here we report that metformin activates AMPK in hepatocytes; as a result, acetyl… Expand

View on PubMed

Share This Paper

4,550 Citations

Highly Influential Citations

301

Background Citations

1,944

Methods Citations

183

Results Citations

Paper Mentions

Observational Clinical Trial

Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly

Cognitive disorders increase with age and in the presence of metabolic diseases such as Type 2 Diabetes Mellitus (T2DM). In addition, digestive disorders, changes in dietary pattern and… Expand

Conditions	Type 2 Diabetes Mellitus
Intervention	Drug

Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

April 2021 - August 2024

Interventional Clinical Trial

Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma

Lung adenocarcinoma with inactive LKB1 has emerged as a particularly aggressive form of lung cancer, with poor response to immune checkpoint inhibitors. Recent preclinical evidences have… Expand

Conditions	Advanced LKB1-inactive Lung Adenocarcinoma
Intervention	Dietary Supplement, Drug

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

October 2018 - September 2023

Interventional Clinical Trial

DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function

Cardiovascular events are the main cause of mortality in diabetic patients ,on the other hand,during an acute myocardial infarction(AMI),hyperglycemia increases mortality and is… Expand

Conditions	Platelet Aggregation During Acute Myocardial Infarction
Intervention	Drug

University of Sao Paulo General Hospital

February 2017 - December 2019

Interventional Clinical Trial

Metformin Pharmacology in Human Cancers: A Proof of Principle Study

This is a presurgical (proof of principle, window of opportunity) study in patients with surgically resectable thoracic tumors to determine steady-state tissue and plasma… Expand

Conditions	Thoracic Neoplasm
Intervention	Drug

Dartmouth-Hitchcock Medical Center

May 2018 - December 2019

Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes.

N. Musi, M. Hirshman, +10 authors L. Goodyear
Chemistry, Medicine
Diabetes
2002

Regulation of glucose-6-phosphatase gene expression by insulin and metformin.

C. Mues, J. Zhou, +6 authors A. Barthel
Biology, Medicine
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2009